LifeVantage (LFVN) Aandelenoverzicht
LifeVantage Corporation houdt zich bezig met het identificeren, onderzoeken, ontwikkelen, formuleren en internationaal verkopen van geavanceerde nutrigenomische activatoren, voedingssupplementen, nootropica, gewichtsbeheersing, pre- en pro-biotica en huid- en haarverzorgingsproducten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 3/6 |
Beloningen
Risicoanalyse
LFVN Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LifeVantage Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$6.25 |
| 52 Week Hoogtepunt | US$15.00 |
| 52 Week Laag | US$3.90 |
| Bèta | 0.76 |
| 1 maand verandering | -34.21% |
| 3 maanden verandering | 50.60% |
| 1 Jaar Verandering | -49.47% |
| 3 jaar verandering | 34.12% |
| 5 jaar verandering | -8.63% |
| Verandering sinds IPO | -74.49% |
Recent nieuws en updates
LFVN: Index Removals And Weaker Margins Will Pressure Future Returns
Analysts have reduced their LifeVantage price target from $12.00 to $5.00, citing updated expectations for lower revenue growth and profit margins, along with a higher future P/E assumption. What’s in the News for LifeVantage LifeVantage was removed from multiple FTSE Russell benchmarks, including the Russell 2000 Growth, Russell 2000 Defensive, Russell 2000 Dynamic, Russell 2500, Russell 3000, Russell 3000E, Russell 3000 Growth, Russell 3000E Growth, Russell 2500 Growth, Russell Small Cap Completeness, and Russell Small Cap Completeness Growth indexes, according to index constituent change updates.
LFVN: Downgrade And Softer Guidance Will Set Up Portugal Expansion Upside
Analysts have trimmed their price target on LifeVantage to $7.00, reflecting a modestly higher discount rate and slightly adjusted P/E assumptions following the latest downgrade in Street research. What’s in the News for LifeVantage LifeVantage updated earnings guidance for the fiscal year ending June 30, 2026, indicating that fiscal 2026 revenue is expected to be close to the lower end of the previously issued guidance range.LFVN: Downgrade And Softer Guidance Will Limit Portugal Expansion Support
Analysts have reduced their fair value estimate for LifeVantage after a recent downgrade in Street research coverage, reflecting a slightly lower discount rate and modestly adjusted expectations for revenue trends, profit margins, and future P/E multiples. What's in the News LifeVantage updated guidance for the fiscal year ending June 30, 2026, and now expects revenue to be close to the lower end of its previously issued range.Recent updates
LFVN: Index Removals And Weaker Margins Will Pressure Future Returns
Analysts have reduced their LifeVantage price target from $12.00 to $5.00, citing updated expectations for lower revenue growth and profit margins, along with a higher future P/E assumption. What’s in the News for LifeVantage LifeVantage was removed from multiple FTSE Russell benchmarks, including the Russell 2000 Growth, Russell 2000 Defensive, Russell 2000 Dynamic, Russell 2500, Russell 3000, Russell 3000E, Russell 3000 Growth, Russell 3000E Growth, Russell 2500 Growth, Russell Small Cap Completeness, and Russell Small Cap Completeness Growth indexes, according to index constituent change updates.LFVN: Downgrade And Softer Guidance Will Set Up Portugal Expansion Upside
Analysts have trimmed their price target on LifeVantage to $7.00, reflecting a modestly higher discount rate and slightly adjusted P/E assumptions following the latest downgrade in Street research. What’s in the News for LifeVantage LifeVantage updated earnings guidance for the fiscal year ending June 30, 2026, indicating that fiscal 2026 revenue is expected to be close to the lower end of the previously issued guidance range.LFVN: Downgrade And Softer Guidance Will Limit Portugal Expansion Support
Analysts have reduced their fair value estimate for LifeVantage after a recent downgrade in Street research coverage, reflecting a slightly lower discount rate and modestly adjusted expectations for revenue trends, profit margins, and future P/E multiples. What's in the News LifeVantage updated guidance for the fiscal year ending June 30, 2026, and now expects revenue to be close to the lower end of its previously issued range.LFVN: Reset Expectations And Portugal Expansion Will Support Future Upside Potential
Analysts cut their price target on LifeVantage from $8 to $7, reflecting a lower fair value estimate, softer profit margin assumptions, and a higher future P/E, following the recent downgrade highlighted in Street research. Analyst Commentary Recent Street commentary points to a more cautious stance on LifeVantage, with the lower price target tied to reassessed earnings power and valuation assumptions following the downgrade.LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential
Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential
Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 26% in the last...LFVN: Gut Health Research Progress Will Support Confident Upside Potential
Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential
Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).LFVN: Gut Study Progress Will Drive Future Upside Potential
Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).LFVN: Future Gut Health Research And Buybacks Will Drive Upside
Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.LFVN: Future Index Inclusion Will Drive Upside Potential
Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).LFVN: Share Repurchases and New Index Addition Will Drive Value
LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 28% in the last...We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks
LifeVantage Corporation ( NASDAQ:LFVN ) shareholders that were waiting for something to happen have been dealt a blow...LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045
The board of LifeVantage Corporation ( NASDAQ:LFVN ) has announced that it will pay a dividend on the 16th of...The LifeVantage Advantage: High Retention, High Returns
Summary LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN’s growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream. Shares trade at a discounted 15.6x forward P/E, below the staples sector median and peers like Nature’s Sunshine, offering valuation upside, alongside dividend yield and liquidity strength. Risks include heavy reliance on one product and retention uncertainty, as subscription fatigue, or competitive GLP-1 alternatives could weaken revenue durability and challenge the bullish case. Read the full article on Seeking AlphaShareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality
When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's...What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
To the annoyance of some shareholders, LifeVantage Corporation ( NASDAQ:LFVN ) shares are down a considerable 26% in...Rendement voor aandeelhouders
| LFVN | US Personal Products | US Markt | |
|---|---|---|---|
| 7D | 0.5% | -1.2% | -0.4% |
| 1Y | -49.5% | -17.3% | 18.4% |
Rendement versus industrie: LFVN presteerde slechter dan de US Personal Products -sector, die het afgelopen jaar een rendement van -17.3 % opleverde.
Rendement versus markt: LFVN presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 18.4 % opleverde.
Prijsvolatiliteit
| LFVN volatility | |
|---|---|
| LFVN Average Weekly Movement | 16.9% |
| Personal Products Industry Average Movement | 8.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: De aandelenkoers van LFVN is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van LFVN is het afgelopen jaar gestegen van 11% naar 17%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| n/a | 235 | Michael Beindorff | www.lifevantage.com |
LifeVantage Corporation houdt zich bezig met het identificeren, onderzoeken, ontwikkelen, formuleren en internationaal verkopen van geavanceerde nutrigenomische activatoren, voedingssupplementen, nootropica, gewichtsbeheersing, pre- en pro-biotica en huid- en haarverzorgingsproducten. Het biedt Protandim, een voedingssupplement; LifeVantage Omega+, een voedingssupplement dat DHA en EPA Omega-3 en Omega-7 vetzuren en vitamine D3 combineert; LifeVantage ProBio, een voedingssupplement om de darmgezondheid te ondersteunen; LifeVantage IC Bright, een supplement om de gezondheid van ogen en hersenen te ondersteunen, vermoeidheid en overbelasting van de ogen te verminderen, cognitieve functies te ondersteunen en normale slaappatronen te ondersteunen; LifeVantage Daily Wellness, een voedingssupplement om de immuungezondheid te versterken; LifeVantage Rise AM en Reset PM System dat het lichaam voorziet van de juiste voedingsstoffen; LifeVantage D3+, een voedingssupplement dat vitamine D3 en K2, magnesium, calcium en andere sporenmineralen levert ter ondersteuning van een evenwichtig immuunsysteem, sterke botten en cardiovasculaire gezondheid; PhysIQ Fat Burn ter ondersteuning van gewichtsbeheersing; PhysIQ Prebiotic is een voedingssupplement ter ondersteuning van de goede bacteriën in de darmen en een gezond microbioom; MindBody GLP-1 System, een voedingssupplement dat twee producten combineert, MB Core en MB Enhance, die zijn ontworpen om gewichtsbeheersing en welzijn te ondersteunen door GLP-1 op natuurlijke wijze te activeren en signalen langs de darm-hersenas in balans te brengen; Petandim for Dogs, een supplement om oxidatieve stress bij honden te bestrijden; en Axio, een nootropische energiedrankmix. Het biedt ook huidverzorgingsproducten tegen veroudering, zoals vloeibaar collageen, gezichtsreinigers, oogcrème, vochtinbrengende crème, zonnebrandcrème, perfectionerende lotions en handcrèmes, evenals shampoos, voedende conditioners en hoofdhuidserums onder de merknaam TrueScience.
LifeVantage Corporation Samenvatting
| LFVN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$78.72m |
| Inkomsten(TTM) | US$5.75m |
| Inkomsten(TTM) | US$195.32m |
Is LFVN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| LFVN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$195.32m |
| Kosten van inkomsten | US$42.70m |
| Brutowinst | US$152.62m |
| Overige uitgaven | US$146.87m |
| Inkomsten | US$5.75m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.46 |
| Brutomarge | 78.14% |
| Nettowinstmarge | 2.94% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde LFVN op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/09 00:56 |
| Aandelenkoers aan het einde van de dag | 2026/07/09 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/06/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
LifeVantage Corporation wordt gevolgd door 5 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Mitchell Pinheiro | Imperial Capital |
| Ryan Meyers | Lake Street Capital Markets, LLC |